Multidimensional profiling of CSF1R screening hits and inhibitors: Assessing cellular activity, target residence time, and selectivity in a higher throughput way

Journal of Biomolecular Screening

Volumn 16, Issue 9, 2011, Pages 1007-1017

  Uitdehaag, Joost C M ^a,b   Sünnen, Cecile M ^a   Van Doornmalen, Antoon M ^a,b   De Rouw, Nikki ^a   Oubrie, Arthur ^a   Azevedo, Rita ^a   Ziebell, Michael ^a   Nickbarg, Elliott ^a   Karstens, Willem Jan ^a   Ruygrok, Simone ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Netherlands Translational Research Center BV   (Netherlands)

Author keywords

cell function assays; cell based assays; enzyme assays or enzyme kinetics; kinases; structure activity relationships

Indexed keywords

COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; DASATINIB; GW 2580; IMATINIB; KI 20227; PYRIDO[2,3-D]PYRIMIDIN 5 ONE; SORAFENIB; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOCHEMISTRY; CELL ACTIVITY; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; ENTROPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; KINETICS; METRIC SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

BINDING, COMPETITIVE; CELL LINE; COMPUTATIONAL BIOLOGY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KINETICS; MAP KINASE SIGNALING SYSTEM; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

EID: 80053533744     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057111418113     Document Type: Article

References (30)

1. Hamilton J. A. Colony-Stimulating Factors in Inflammation and Autoimmunity. Nat. Rev. Immunol. 2008 ; 8: 533-544 (Pubitemid 351913679)
2. Chitu V., Stanley E. R. Colony-Stimulating Factor-1 in Immunity and Inflammation. Curr. Opin. Immunol. 2006 ; 18: 39-48 (Pubitemid 43049646)
3. Patel S., Player M. R. Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease. Curr. Topics Med. Chem. 2009 ; 9: 599-610
4. Manthey C. L., Player M. R. Advances in the Discovery of Anti-Inflammatory FMS Inhibitors. Ann. Med. Chem. 2009 ; 44: 211-225
5. Conway J. G., McDonald B., Parham J., Keith B., Rusnak D. W., Shaw E., Jansen M., Lin P., Payne A., Crosby R. M., et al. Inhibition of Colony-Stimulating-Factor-1 Signaling In Vivo with the Orally Bioavailable cFMS Kinase Inhibitor GW-2580. Proc. Natl. Acad. Sci. U. S. A. 2005 ; 102: 16078-16083 (Pubitemid 41552870)
6. Ohno H., Kubo K., Murooka H., Kobayashi Y., Nishitoba T., Shibuya M., Yoneda T., Isoe T. A cFms Tyrosine Kinase Inhibitor, Ki-20227, Suppresses Osteoclast Differentiation and Osteolytic Bone Destruction in a Bone Metastasis Model. Mol. Cancer Ther. 2006 ; 5: 2634-2643 (Pubitemid 44848990)
7. Jack G. D., Zhang L., Friedman A. D. M-CSF Elevates c-Fos and Phospho-C/EBPα (S21) via ERK Whereas G-CSF Stimulates SHP2 Phosphorylation in Marrow Progenitors to Contribute to Myeloid Lineage Specification. Blood. 2009 ; 114: 2172-2180
8. Karaman M. W., Herrgard S., Treiber D. K., Gallant P., Atteridge C. E., Campbell B. T., Chan K. W., Ciceri P., Davis M. I., Edeen P. T., et al. A Quantitative Analysis of Kinase Inhibitor Selectivity. Nat. Biotech. 2008 ; 26: 127-132
9. Brownlow N., Vaid M., Dibb N. J. Tandutinib Inhibits Fms Receptor Signalling, and Macrophage and Osteoclast Formation In Vitro. Leukemia. 2008 ; 22: 1452-1453 (Pubitemid 352006094)
10. Huang H., Hutta D. A., Rinker J. M., Huaping H., Parsons W. H., Schubert C., DesJarlais R. L., Crysler C. S., Chaikin M. A., Donatelli R. R., et al. Pyrido[2,3-d]pyrimidin-5-ones: A Novel Class of Anti-Inflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors. J. Med. Chem. 2009 ; 52: 1081-1099
11. Shun T. Y., Lazo J. S., Sharlow E. R., Johnston P. A. Identifying Actives from HTS Data Sets: Practical Approaches for the Selection of an Appropriate HTS Data-Processing Method and Quality Control Review. J. Biomol. Screen. 2011 ; 16: 1-14
12. Goldstein D. M., Gray N. S., Zarrinkar P. P. High Throughput Kinase Profiling as a Platform for Drug Discovery. Nat. Rev. Drug Discov. 2008 ; 7: 391-397 (Pubitemid 351619111)
13. Zuccotto F., Ardini E., Casale E., Angiolini M. Through the 'Gatekeeper Door': Exploiting the Active Kinase Conformation. J. Med. Chem. 2010 ; 53: 2681-2694
14. Johnson L. Protein Kinase Inhibitors: Contributions from Structure to Clinical Compounds. Q. Rev. Biophys. 2009 ; 42: 1-40
15. Simard J. L., Klüter S., Grütter C., Getlik M., Rabiller M., Rode H. B., Rauh D. A New Screening Assay for Allosteric Inhibitors of cSrc. Nat. Chem. Biol. 2009 ; 5: 394-396
16. Copeland R. A., Pompliano D. L., Meek T. D. Drug Target Residence Time and Its Implications for Lead Optimization. Nat. Rev. Drug Discov. 2006 ; 5: 730-739 (Pubitemid 44323700)
17. Lu H., Tonge P. J. Drug-Target Residence Time: Critical Information for Lead Optimization. Curr. Opin. Chem. Biol. 2010 ; 14: 467-474
18. Pargellis C., Tong L., Churchill L., Cirillo P. F., Gilmore T., Graham A. G., Grob P. M., Hickey E. R., Moss N., Pav S., et al. Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site. Nat. Struct. Biol. 2002 ; 9: 268-272 (Pubitemid 34289898)
19. Annis D. A., Athanasopoulos J., Curran P. J., Felsch J. S., Kalghatgi K., Lee W. H. An Affinity Selection-Mass Spectrometry Method for the Identification of Small Molecule Ligands from Self-Encoded Combinatorial Libraries: Discovery of a Novel Antagonist of E. coli Dihydrofolate Reductase. Int. J. Mass Spectrometry. 2004 ; 238: 77-83
20. Motulsky H. J., Mahan L. C. The Kinetics of Competitive Radioligand Binding Predicted by the Law of Mass Action. Mol. Pharm. 1984 ; 25: 1-9 (Pubitemid 14223246)
21. Zaman G. J., de Roos J. A., Blomenröhr M., van Koppen C. J., Oosterom J. Cryopreserved Cells Facilitate Cell-Based Drug Discovery. Drug Discov. Today. 2007 ; 12: 521-526 (Pubitemid 47039304)
22. Uitdehaag J. C. M., Zaman G. J. A Theoretical Entropy Score as a Single Value to Express Inhibitor Selectivity. BMC Bioinform. 2011 ; 12: 94
23. Wodicka L. M., Ciceri P., Davis M. I., Hunt J. P., Floyd M., Salerno S., Hua X. H., Ford J. M., Armstrong R. C., Zarrinkar P. P.;, et al. Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry. Chem. Biol. 2010 ; 17: 1241-1249
24. Meyers M. J., Pelc M., Kamtekar S., Day J., Poda G. I., Hall M. K., Michener M. L., Reitz B. A., Mathis K. J., Pierce B. S., et al. Structure-Based Drug Design Enables Conversion of a DFG-in Binding CSF-1R Kinase Inhibitor to a DFG-out Binding Mode. Bioorg. Med. Chem. Lett. 2010 ; 20: 1543-1547
25. Walter M., Lucet I. S., Patel O., Broughton S. E., Bamert R., Williams N. K., Fantino E., Wilks A. F., Rossjohn J. The 2.7 Å Crystal Structure of the Autoinhibited Human c-Fms Kinase Domain. J. Mol. Biol. 2007 ; 367: 839-847 (Pubitemid 46330380)
26. Gajiwala K. S., Wu J. C., Christensen J., Deshmukh G. D., Diehl W., DiNitto J. P., English J. M., Greig M. J., He Y. A., Jacques S. L., et al. KIT Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients. Proc. Natl. Acad. Sci. U. S. A. 2009 ; 106: 1542-1547
27. Arányi P. Kinetics of the Hormone-Receptor Interaction: Competition Experiments with Slowly Equilibrating Ligands. Biochim. Biophys. Acta. 1980 ; 628: 220-227 (Pubitemid 10097246)
28. Brandt P., Jenmalm Jensen A., Nilsson J. Small Assay Panels Can Provide a Measure of Selectivity. Bioorg. Med. Chem. Lett. 2009 ; 19: 5861-5863
29. Hancock M. K., Lebakken C. S., Wang J., Bi K. Multi-Pathway Cellular Analysis of Compound Selectivity. Mol. Biosyst. 2010 ; 6: 1834-1843
30. Simard J. R., Grütter C., Pawar V., Aust B., Wolf A., Rabiller M., Wulfert S., Robubi A., Klüter S., Ottmann C., et al. High-Throughput Screening to Identify Inhibitors Which Stabilize Inactive Kinase Conformations in p38α. J. Am. Chem. Soc. 2009 ; 131: 18478-18488